Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model.
Heliyon
; 9(6): e16664, 2023 Jun.
Article
in English
| MEDLINE | ID: covidwho-2327879
ABSTRACT
The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and in vivo data have suggested that Sotrovimab could retain partial activity against recent omicron sub-lineage such as BA.5 variants, including BQ.1.1. Here we report full efficacy of Sotrovimab against BQ.1.1 viral replication as measure by RT-qPCR in a non-human primate challengemodel.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Topics:
Variants
Language:
English
Journal:
Heliyon
Year:
2023
Document Type:
Article
Affiliation country:
J.heliyon.2023.e16664
Similar
MEDLINE
...
LILACS
LIS